Chemotherapy-related cognitive impairment and non-pharmacological interventions targeting the nervous system: a systematic review - Top-Institutions - MDSpire

Chemotherapy-related cognitive impairment and non-pharmacological interventions targeting the nervous system: a systematic review

  • By

  • Norbert Dosa

  • Intouch Limvaree

  • Camila Bonin Pinto

  • Faddi Saleh Velez

  • Zalan Kaposzta

  • Zsofia Szarvas

  • Zachary C. Pope

  • Anna Csiszar

  • Wajeeha Razaq

  • Ryan D. Nipp

  • Andriy Yabluchanskiy

  • Peter Mukli

  • June 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Neuroscience

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Survivorship Care

  • #3

    Washington University School of Medicine in St. Louis
    Washington University School of Medicine in St. Louis

    St. Louis, Missouri

    Key Differentiators

    • Oncology
    • Radiation Oncology

  • #4

    The Ohio State University Wexner Medical Center
    The Ohio State University Wexner Medical Center

    Columbus, Ohio

    Key Differentiators

    • Oncology
    • Cancer Rehabilitation

  • #5

    University of California, Los Angeles, Jonsson Comprehensive Cancer Center
    University of California, Los Angeles, Jonsson Comprehensive Cancer Center

    Los Angeles, California

    Key Differentiators

    • Oncology
    • Cancer Prevention

Original Source(s)

Chemotherapy-related cognitive impairment and non-pharmacological interventions targeting the nervous system: a systematic review

  • by Norbert Dosa, Intouch Limvaree, Camila Bonin Pinto, Faddi Saleh Velez, Zalan Kaposzta, Zsofia Szarvas, Zachary C. Pope, Anna Csiszar, Wajeeha Razaq, Ryan D. Nipp, Andriy Yabluchanskiy, Peter Mukli

  • June 2, 2026

Related Content

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

  • by

  • June 1, 2026

  • 4 min
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU